Search results
Jul 7, 2023 · Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight management. While tirzepatide may potentially be more effective, it's too early to know that based on current research.
Mar 10, 2024 · Both tirzepatide and semaglutide are prescription medicines used with diet and exercise to treat people with type 2 diabetes or to help people lose and maintain weight loss. They are marketed as the brand name products Ozempic, Rybelsus or Wegovy (semaglutide) and Mounjaro or Zepbound (tirzepatide).
Jun 25, 2021 · At all doses, tirzepatide was superior to semaglutide, with estimated treatment differences of −1.9 kg (95% CI, −2.8 to −1.0) with tirzepatide at a dose of 5 mg, −3.6 kg (95% CI, −4.5 to...
Mar 3, 2022 · The recently introduced peptides semaglutide and tirzepatide can be administered once weekly and have demonstrated substantially improved weight-losing effects within a tolerable safety margin in a series of STEP and SURPASS trials.
Jul 8, 2024 · In this large clinical analysis of US adults with overweight or obesity who initiated tirzepatide or semaglutide treatment, those receiving tirzepatide were more likely to achieve 5% or greater, 10% or greater, and 15% or greater weight loss and experienced larger reductions in body weight at 3, 6, and 12 months.
At all doses, tirzepatide was superior to semaglutide, with estimated treatment differences of −1.9 kg (95% CI, −2.8 to −1.0) with tirzepatide at a dose of 5 mg, −3.6 kg (95% CI, −4.5 to...
Jun 4, 2022 · Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the...
Aug 5, 2021 · Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons).
Jun 1, 2021 · The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide (TZP) is in development for type 2 diabetes (T2D). Efficacy and safety of once weekly TZP vs. semaglutide (SEMA) was assessed in people with T2D on background metformin.
Apr 13, 2024 · Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (mean difference −21.61 mmol/mol [−1.96%]) followed by tirzepatide 10 mg (−20.19 mmol/mol [−1.84%]), semaglutide 2.0 mg (−17.74 mmol/mol [−1.59%]), tirzepatide 5 mg (−17.60 mmol/mol [−1.60%]), semaglutide 1.0 mg (−15.25 mmol/mol [− ...
